Summary of Study ST002302
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001475. The data can be accessed directly via it's Project DOI: 10.21228/M82M60 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002302 |
| Study Title | Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab |
| Study Summary | Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 receptors, has been widely used in AD because of its efficacy. However, metabolic changes occurring in patients with AD in response to dupilumab remains unknown. In this study, we integrated metabolomics and lipidomics analyses with clinical data to explore potential metabolic alterations associated with dupilumab therapeutic efficacy. In addition, we investigate whether the development of treatment side effects was linked to the dysregulation of metabolic pathways. Methods: A total of 33 patients with AD were included in the current study, with serum samples collected before and after treatment with dupilumab. Comprehensive metabolomic and lipidomic analyses have previously been developed to identify serum metabolites (including lipids) that vary among treatment groups. An orthogonal partial least squares discriminant analysis model was established to screen for differential metabolites and metabolites with variable importance in projection > 1 and p < 0.05 were considered potential metabolic biomarkers. MetaboAnalyst 5.0 was used to identify related metabolic pathways. Patients were further classified into two groups, well responders (n = 19) and poor responders (n = 14), to identify differential metabolites between the two groups. Results: The results revealed significant changes in serum metabolites before and after 16 weeks of dupilumab treatment. Variations in the metabolic profile were more significant in the well-responder group than in the poor-responder group. Pathway enrichment analysis revealed that differential metabolites derived from the well-responder group were mainly involved in glycerophospholipid metabolism, valine, leucine and isoleucine biosynthesis, the citrate cycle, arachidonic acid metabolism, pyrimidine metabolism, and sphingolipid metabolism. Conclusion: Serum metabolic profiles of patients with AD varied significantly after treatment with dupilumab. Differential metabolites and their related metabolic pathways may provide clues for understanding the effects of dupilumab on patient metabolism. |
| Institute | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
| Last Name | Zhang |
| First Name | Lishan |
| Address | No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China. |
| 429647356@qq.com | |
| Phone | +86-18612636397 |
| Submit Date | 2022-10-01 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | GC-MS/LC-MS |
| Release Date | 2022-10-18 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU002388 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | >=18 |
| Gender: | Male and female |
| Human Race: | Chinese |
| Human Ethnicity: | Han |
| Human Trial Type: | observational study |
| Human Medications: | Dupilumab |
| Human Inclusion Criteria: | 1.Age ≥ 18 years of age 2.Dermatologist diagnosis of moderate to severe AD, EASI≥16 at baseline 3.Eligible to receive dupilumab therapy for AD in accordance with the guidelines. Patients who are eligible were treated with a fixed schedule of 300mg dupilumab in 2-week intervals. Patients who did not achieve 16-week therapy were excluded. 4.During the whole treatment process, the requirements for diet and exercise are roughly the same as before treatment, so as to keep the body healthy and balanced 5.A 30-day washout period of systemic medications preceded treatment |
| Human Exclusion Criteria: | 1Evidence of other skin diseases except for AD at baseline 2.Pregnancy or breast feeding, 3.Patients with permanent severe diseases, especially those affecting the immune system, except asthma 4.Patients with severe mental illness 5.Evidence of chronic metabolic disease, including Obesity, diabetes, fatty liver, osteoporosis, atherosclerotic cardiovascular and cerebrovascular diseases, and metabolic-related cancers (breast, colorectal, pancreatic, colon, and prostate cancer). 6.Application of other systemic medications during treatment |
